FDA Keynote Presentation at CPhI North America 2018

News
Article

Peter Stein, MD will present FDA’s keynote presentation at the CPhI North America conference on Thursday, April 26, 2018 in Philadelphia, PA.

Peter Stein, MD, deputy director, Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), FDA will present FDA’s keynote presentation at the CPhI North America conference on Thursday, April 26, 2018 in Philadelphia, PA. Stein joined FDA in late 2016 as the deputy director at the OND, CDER. 

In 1999, he joined Bristol-Myers Squibb and later held various positions at Merck and Janssen, finishing his industry career at Merck as vice-president for Late-Stage Development in Diabetes and Endocrinology. During his industry career, Stein led development programs for several currently approved diabetes medications, and has worked on a range of programs from discovery through early and late clinical development.

He earned his medical degree from University of Pennsylvania and trained at Yale-New Haven Hospital in internal medicine, endocrinology, and metabolism. Stein was also on faculty at Yale in the Section of Endocrinology and served as the associate program director for the Primary Care Residency Program.  Additionally, he was the section chief for Endocrinology and the program director for the internal medicine residency program at the Medical College of Georgia.  

Stein is currently a clinical associate professor at the Robert Wood Johnson Medical School, where he once maintained an endocrinology practice. 

For more information and to register for the event, please visit www.cphinorthamerica.com.

Source: CPhI North America

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.